A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.
The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine
作者:Malte Meppen、Barbara Pacini、Renzo Bazzo、Uwe Koch、Joseph F. Leone、Kenneth A. Koeplinger、Michael Rowley、Sergio Altamura、Annalise Di Marco、Fabrizio Fiore、Claudio Giuliano、Odalys Gonzalez-Paz、Ralph Laufer、Vincenzo Pucci、Frank Narjes、Cristina Gardelli
DOI:10.1016/j.ejmech.2009.04.043
日期:2009.9
The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2'-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes. (C) 2009 Elsevier Masson SAS. All rights reserved.